Oral-Periodontal Evaluation and Assessment of Biomarkers in Oral Fluids in Patients With Hepatitis B+D Treated With Bulevirtide
Periodontal disease is a chronic inflammatory condition associated with systemic diseases, highlighting the concept of periodontal medicine. This study aims to investigate the relationship between periodontal inflammation, oral lesions, and hepatitis B+D infection, with or without bulevirtide treatment. Oral-periodontal clinical parameters and targeted inflammatory biomarkers in saliva and gingival crevicular fluid will be evaluated in three groups: patients with hepatitis B+D receiving bulevirtide, patients with hepatitis B+D not receiving bulevirtide, and healthy controls.
• Adults (≥18 years old) capable of providing informed consent.
• For Hepatitis B+D groups: confirmed hepatitis B and D co-infection.
• Bulevirtide group: receiving bulevirtide therapy as prescribed.
• No Bulevirtide group: not receiving bulevirtide.
• For Healthy Control group: systemically healthy adults without hepatitis B or D infection.
• Willingness to undergo oral-periodontal examination, saliva and gingival crevicular fluid collection, and oral cavity photography.